Why RabMAbs make better stem cell antibodies▸
Interactive Pluripotency Pathway Map▸
A panel of RabMAbs to core pluripotent stem cell markers▸
Why RabMAbs® make better stem cell antibodies?
The rabbit immune system responds better to difficult antigens than the mouse immune system (1). This is critical for the development of high quality antibodies. Epitomics Rabbit Monoclonal Antibodies (RabMAbs) provide the combined benefits of superior antigen recognition of the rabbit immune system with the specificity and consistency of a monoclonal antibody, bringing you the highest quality antibody possible (2,3).
Epitomics has developed various high quality stem cell marker antibodies, including a panel of RabMAbs to core pluripotent stem cell markers - SOX2, OCT4, Nanog, LIN28 (see below for additional data).
Additionally, Epitomics validates every RabMAb in western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and flow cytometry before release, so you can be assured of which assays the antibody will work in.
Pluripotency Pathway Map
Pluripotent stem cells have the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system). Additionally, pluripotent stem cells can differentiate into germ cells (teratome, female or male germ cells). Please see below for an interactive pathway map featuring markers for various stages of pluripotency, including the core pluripotency transcription network markers (SOX2, OCT4, Nanog and Lin28).
Click on the image for the interactive version
A panel of RabMAbs to core pluripotent stem cell markers
Pluripotent embryonic stem cells have the ability to differentiate into cells of all three germ layers. This ability strongly correlates with the expression of main pluripotent cells markers, such as SOX2, OCT4, Nanog and Lin28. The same transcription factors have been overexpressed in various types of germ cell tumors (GCT). We have developed a panel of rabbit monoclonal antibodies (RabMAbs) to these to the core pluripotency transcription network markers, developing a major tool in the diagnostic and distinguishing of GCTs.
LIN28 |
||
|---|---|---|
 |
|
|
| Immunohistochemical analysis of paraffin-embedded human dysgerminoma tissue using anti-LIN28 RabMAb | Immunofluorescent staining of embrionic carcinoma cell line using anti-LIN28 RabMAb | Immunohistochemical analysis of paraffin-embedded human seminoma tissue using anti-LIN28 RabMAb |
Catalog #3533-1
|
Nanog |
||
|---|---|---|
 |
 |
 |
| Immunofluorescent staining of embrionic carcinoma cell line using anti-Nanog RabMAb | Immunohistochemical analysis of paraffin-embedded human dysgerminoma tissue using anti-Nanog RabMAb | Immunohistochemical analysis of paraffin-embedded human seminoma tissue using anti-Nanog RabMAb |
Catalog #3369-1
|
OCT4 |
||
|---|---|---|
 |
 |
 |
| Immunohistochemical analysis of paraffin-embedded human fetal brain using anti-OCT4 RabMAb | Immunohistochemical analysis of paraffin-embedded human ovarian dysgerminoma using anti-OCT4 RabMAb | Immunohistochemical analysis of paraffin-embedded human seminoma using anti-OCT4 RabMAb |
Catalog #2876-1
|
SOX2 |
||
|---|---|---|
 |
 |
 |
| Immunohistochemical analysis of paraffin-embedded human glioma using anti-SOX2 RabMAb | Immunohistochemical analysis of paraffin-embedded human embrionic carcinoma using anti-SOX2 RabMAb | Immunohistochemical analysis of paraffin-embedded human fetal brain using anti-SOX2 RabMAb |
Catalog #2683-1
|
References
1. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. Rocha R, et al., [Pathol Res Pract, 2008;204(9):655-62. Epub 2008 Jun 18]
2.
A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models Yu Y, et al., [PLoS One. 2010 Feb 5;5(2):e9072]
3. Rabbit monoclonal antibody: potential application in cancer therapy Lifeng Feng, Xian Wang, and Hongchuan Jin [Am J Transl Res. 2011 May 15; 3(3): 269–274]
